Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CD166 Antikörper

ALCAM Reaktivität: Human WB, IP, IHC (p), IHC (fro), IF, Func Wirt: Maus Monoclonal AZN-L50 unconjugated
Produktnummer ABIN2191863
  • Target Alle CD166 (ALCAM) Antikörper anzeigen
    CD166 (ALCAM) (Activated Leukocyte Cell Adhesion Molecule (ALCAM))
    Reaktivität
    • 87
    • 28
    • 22
    • 17
    • 2
    • 1
    Human
    Wirt
    • 63
    • 35
    • 3
    • 1
    Maus
    Klonalität
    • 66
    • 36
    Monoklonal
    Konjugat
    • 46
    • 14
    • 10
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser CD166 Antikörper ist unkonjugiert
    Applikation
    • 65
    • 39
    • 32
    • 27
    • 13
    • 13
    • 13
    • 7
    • 5
    • 5
    • 5
    • 5
    • 2
    • 2
    • 2
    • 1
    • 1
    Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunofluorescence (IF), Functional Studies (Func)
    Sterilität
    0.2 μm filtered
    Klon
    AZN-L50
    Top Product
    Discover our top product ALCAM Primärantikörper
  • Applikationshinweise
    For immunohistology, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Buffer
    PBS, containing 0.1 % bovine serum albumin
    Lagerung
    4 °C
    Informationen zur Lagerung
    Product should be stored at 4 °C Under recommended storage conditions, product is stable for one year.
    Haltbarkeit
    12 months
  • van Kilsdonk, Wilting, Bergers, van Muijen, Schalkwijk, van Kempen, Swart: "Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule." in: Cancer research, Vol. 68, Issue 10, pp. 3671-9, (2008) (PubMed).

    Te Riet, Zimmerman, Cambi, Joosten, Speller, Torensma, van Leeuwen, Figdor, de Lange: "Distinct kinetic and mechanical properties govern ALCAM-mediated interactions as shown by single-molecule force spectroscopy." in: Journal of cell science, Vol. 120, Issue Pt 22, pp. 3965-76, (2007) (PubMed).

    Zimmerman, Joosten, Torensma, Parnes, van Leeuwen, Figdor: "Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells." in: Blood, Vol. 107, Issue 8, pp. 3212-20, (2006) (PubMed).

    van Kempen, Nelissen, Degen, Torensma, Weidle, Bloemers, Figdor, Swart: "Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction." in: The Journal of biological chemistry, Vol. 276, Issue 28, pp. 25783-90, (2001) (PubMed).

  • Target
    CD166 (ALCAM) (Activated Leukocyte Cell Adhesion Molecule (ALCAM))
    Andere Bezeichnung
    CD166 (ALCAM Produkte)
    Synonyme
    CD166 antikoerper, MEMD antikoerper, ALCAM antikoerper, BEN antikoerper, DM-GRASP antikoerper, JC7 antikoerper, SC1 antikoerper, AI853494 antikoerper, MuSC antikoerper, alcam antikoerper, cd166 antikoerper, memd antikoerper, fb53h09 antikoerper, fb80a10 antikoerper, nlcam antikoerper, si:ch211-190h2.4 antikoerper, wu:fb53h09 antikoerper, wu:fb80a10 antikoerper, wu:fc14b01 antikoerper, activated leukocyte cell adhesion molecule antikoerper, activated leukocyte cell adhesion molecule a antikoerper, activated leukocyte cell adhesion molecule L homeolog antikoerper, CD166 antigen homolog antikoerper, activated leukocyte cell adhesion molecule b antikoerper, ALCAM antikoerper, Alcam antikoerper, alcama antikoerper, alcam.L antikoerper, alcam antikoerper, cd166 antikoerper, alcamb antikoerper
    Hintergrund
    The monoclonal antibody AZN-L50 recognizes activated leukocyte cell adhesion molecule (ALCAM), a member of the immunoglobulin superfamily and has a characteristic VVC2C2C2 domain structure. ALCAM is a type I transmembrane protein of 100 kDa with five extracellular immunoglobulin-like domains and a short cytoplasmic tail. ALCAM mediates homotypic ALCAM-ALCAM interactions and heterotypic interactions with the T-cell antigen CD6. Homotypic interactions are involved in the development and maintenance of tissue architecture and tumor progression. Heterotypic interactions initiate and stabilize T- cell-dendritic interactions affecting T-cell activation. ALCAM is secreted as a NH2-terminal fragment of 30 kD. Soluble ALCAM (sALCAM) induces divergent biological signals and responses. ALCAM shows a characteristic, temporal and spatial distribution in development of a wide variety of tissues and cells in health and disease. ALCAM is expressed on a wide variety of cells, within the leukocyte population its expression is particularly high on dentritic cells. ALCAM is involved in various physiological processes including hematopoieses, thymus development, the immune response, neurite extension, neural cell migration, embryogenesis, neurogenesis, angiogenesis, osteogenesis and is a marker for pluripotent mesenchymal stem cells. The monoclonal antibody AZN-L50 completely blocks homophilic ALCAM-ALCAM interaction. Aliases Activated leukocyte cell adhesion molecule, ALCAM, CD166, Immunogen CD166 expressing K562 cells
Kundenservice